ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026
Trajectories of psychotic symptoms and fronto-parietal resting state functional connectivity MRI following an antipsychotic trial in medication-naïve first-episode psychosis patients.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Glutamate, Brain Connectivity and Duration of Untreated Psychosis
Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study in Medication-naïve First Episode Psychosis Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Evidence of heterogeneity in the trajectory of psychosis is abundant. Here, we applied group-based trajectory modeling on positive symptoms and collected resting state fMRI data of 81 medication-naïve first episode psychosis (FEP) patients during a 16-week antipsychotic drug (APD) trial. Data from 131 healthy controls (HCs) were also acquired during the trial for comparison. Three major trajectory subgroups were identified and labeled as Fast (50.6%), Delay (35.8%), and Partial responders (13.6%). Logistic regressions revealed that Fast responders (vs. Partial) showed significantly lower psychopathology symptoms prior to treatment and lower APD dosage after the trial. Moreover, Delay responders showed significant increases in executive control network resting state functional connectivity (ECN FC) during the trial towards a normalization (using HCs as reference), while Fast and Partial responders to a lesser extent. These changes were associated with treatment response (reduction in positive symptoms after the trial). Future work should harness the potential of ECN FC to inform the mechanism of delayed responses with the potential to start unraveling psychotic heterogeneity which has hampered our ability to identify new treatment strategies and lead to better clinical outcomes. (Clinical trial registration: Trajectories of Treatment Response as Window into the Heterogeneity of Psychosis: A Longitudinal Multimodal Imaging Study, NCT03442101 https://clinicaltrials.gov/ct2/show/NCT03442101 . Glutamate, Brain Connectivity and Duration of Untreated Psychosis (DUP), NCT02034253 https://clinicaltrials.gov/ct2/show/NCT02034253 ).
Identifiers
42629434What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.